Recent advances in non-small cell lung cancer targeted therapy; an update review

Area of Science:

• Oncology
• Molecular Biology
• Translational Research

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Molecular translational research has driven significant progress in non-small cell lung cancer (NSCLC) diagnosis and treatment.
• Targeted therapy has emerged as a highly successful therapeutic approach for NSCLC.

Purpose of the Study:

• To comprehensively discuss tumor target antigens in NSCLC.
• To review targeted therapy agents for NSCLC treatment.
• To summarize current clinical trial data for NSCLC patients.

Main Methods:

• Review of molecular translational research advancements in NSCLC.
• Analysis of targeted therapy mechanisms, including gene and protein antagonists.
• Compilation and summary of existing clinical trial studies for NSCLC.

Main Results:

• Targeted therapy demonstrates successful outcomes by selectively blocking tumor growth pathways.
• Advances in understanding tumor antigens and developing targeted agents are rapidly evolving NSCLC treatment.
• Clinical trials provide crucial data on the efficacy and safety of targeted therapies in NSCLC.

Conclusions:

• Targeted therapy represents a cornerstone in modern NSCLC management, improving patient outcomes and quality of life.
• Continued research into tumor targets and novel agents is essential for advancing NSCLC treatment.
• The integration of clinical trial findings is vital for optimizing targeted therapy strategies in NSCLC.